201 related articles for article (PubMed ID: 16898076)
1. Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. II: study in healthy volunteers.
Popović J; Mitić R; Sabo A; Mikov M; Jakovljević V; Daković-Svajcer K
Eur J Drug Metab Pharmacokinet; 2006; 31(2):87-96. PubMed ID: 16898076
[TBL] [Abstract][Full Text] [Related]
2. Validation of the hepatic blood flow rate model for verapamil first-pass metabolism.
Popović J
Eur J Drug Metab Pharmacokinet; 2007; 32(1):13-9. PubMed ID: 17479539
[TBL] [Abstract][Full Text] [Related]
3. Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. I: conceptual and numerical issues.
Popović J
Eur J Drug Metab Pharmacokinet; 2006; 31(2):79-85. PubMed ID: 16898075
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of verapamil and its metabolite norverapamil from a buccal drug formulation.
Sawicki W; Janicki S
Int J Pharm; 2002 May; 238(1-2):181-9. PubMed ID: 11996822
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of the controlled-release nisoldipine coat-core tablet formulation.
Heinig R; Ahr G; Hayauchi Y; Kuhlmann J
Int J Clin Pharmacol Ther; 1997 Aug; 35(8):341-51. PubMed ID: 9266290
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.
Markowitz JS; Straughn AB; Patrick KS; DeVane CL; Pestreich L; Lee J; Wang Y; Muniz R
Clin Pharmacokinet; 2003; 42(4):393-401. PubMed ID: 12648029
[TBL] [Abstract][Full Text] [Related]
7. [Bioavailability of two verapamil formulations following repeated administration in steady-state conditions. An open, two-period, crossover study].
Heintz B; Müller A; Lenhard G; Schütz M; Hutt HJ
Arzneimittelforschung; 1996 Nov; 46(11):1060-3. PubMed ID: 9065315
[TBL] [Abstract][Full Text] [Related]
8. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.
Marcelín-Jiménez G; Angeles-Moreno AP; Contreras-Zavala L; Morales-Martínez M; Rivera-Espinosa L
Clin Ther; 2009 Sep; 31(9):2002-11. PubMed ID: 19843490
[TBL] [Abstract][Full Text] [Related]
9. High variability in drug pharmacokinetics complicates determination of bioequivalence: experience with verapamil.
Tsang YC; Pop R; Gordon P; Hems J; Spino M
Pharm Res; 1996 Jun; 13(6):846-50. PubMed ID: 8792420
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of verapamil and norverapamil from controlled release floating pellets in humans.
Sawicki W
Eur J Pharm Biopharm; 2002 Jan; 53(1):29-35. PubMed ID: 11777750
[TBL] [Abstract][Full Text] [Related]
11. Modulation of drug release by utilizing pH-independent matrix system comprising water soluble drug verapamil hydrochloride.
Baviskar D; Sharma R; Jain D
Pak J Pharm Sci; 2013 Jan; 26(1):137-44. PubMed ID: 23261739
[TBL] [Abstract][Full Text] [Related]
12. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
13. Intra-gastric performance and bioavailability study of a new per-oral bioadhesive Verapamil HCl matrix tablet in dogs.
Yassin AE; Alkhaled F; al-Suwayeh S; Elkheshen S
Boll Chim Farm; 2003 Sep; 142(7):285-9. PubMed ID: 14677272
[TBL] [Abstract][Full Text] [Related]
14. Bioequivalence and relative bioavailability of a new diltiazem sustained release formulation.
Scheiwe MW; Lankhaar G; Kleinbloesem CH
Arzneimittelforschung; 1996 Oct; 46(10):960-3. PubMed ID: 8931888
[TBL] [Abstract][Full Text] [Related]
15. Sustained-release verapamil: multiple-dose pharmacokinetic comparison of 120-mg and 240-mg tablets and the effect of halving a 240-mg tablet.
McEwen J; Durnin C; McMurdo ME; Moreland TA
J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S57-9. PubMed ID: 2475689
[TBL] [Abstract][Full Text] [Related]
16. Effects of food on the bioequivalence of different verapamil sustained-release formulations.
Waldman SA; Morganroth J
J Clin Pharmacol; 1995 Feb; 35(2):163-9. PubMed ID: 7751427
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of verapamil and norverapamil in patients with hypertension: a comparison of oral conventional and sustained release formulations.
Jørgensen NP; Walstad RA
Pharmacol Toxicol; 1988 Aug; 63(2):105-7. PubMed ID: 3186615
[TBL] [Abstract][Full Text] [Related]
18. Effect of delayed administration of activated charcoal on the absorption of conventional and slow-release verapamil.
Laine K; Kivistö KT; Neuvonen PJ
J Toxicol Clin Toxicol; 1997; 35(3):263-8. PubMed ID: 9140320
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of verapamil and norverapamil enantiomers after administration of immediate and controlled-release formulations to humans:evidence suggesting input-rate determined stereoselectivity.
Bhatti MM; Lewanczuk RZ; Pasutto FM; Foster RT
J Clin Pharmacol; 1995 Nov; 35(11):1076-82. PubMed ID: 8626881
[TBL] [Abstract][Full Text] [Related]
20. Bioavailability study of two different verapamil formulations.
Horne C; Stenzhorn G; Blume H; Knauf H; Mutschler E
Arch Pharm (Weinheim); 1992 Aug; 325(8):531-6. PubMed ID: 1417461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
